Compare Citius Pharmaceuticals Inc (CTXR) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.5 (market cap $962.24M). The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is far larger — about 70.6× Citius Pharmaceuticals Inc's market cap, and Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 57 Days on average.
| CTXR | QDTE | |
|---|---|---|
Market Cap | $13.62M | $962.24M |
Volume | 132,438 | 882,859 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $36.60 |
52-Week Low | $0.48 | $26.85 |
Typical Hold Time | 17 Days | 57 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.50, down 1.3% today amid bearish technical signals. The ETF generates weekly income through covered call strategies on Nasdaq-100 components, with recent distributions ranging from $0.11-$0.28. Technical indicators show mixed signals with overall bearish momentum, while fundamental data remains limited for this specialized income-focused product.
The outlook remains cautious as declining volatility pressures distribution yields, with recent payouts suggesting a more sustainable 24-31% annualized yield versus the trailing 43%. Key risks include NAV erosion from return of capital and underperformance in bull markets due to capped upside potential from daily call writing strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
